ULBI Earnings

ULBI reported its earnings on 2026-03-10, showcasing a revenue of 48.48M against an estimate of 57.00M, resulting in a -14.95% surprise. The EPS was 0.12, surpassing the expected 0.27 by -55.56%. The stock experienced a 7.61% price change on the earnings day and a 23% change over the next five days, reflecting market reactions to the results.

Following ULBI's earnings announcement on 2026-03-10, the stock price moved by 7.61% on the day of the release. Over the subsequent five days, it saw a 23% change. Historically, ULBI's stock price tends to shift by an average of -0.37% in the 10 days leading up to earnings and -0.77% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate ULBI's annual revenue to reach 52.40M, while the EPS is projected at 0.16. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ULBI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ULBI's stock price typically moves by -0.37% in the 10 days before its earnings and -0.77% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.16 and revenue of 52.40M.

The earnings call highlights a mixed financial performance with strong revenue growth in Battery & Energy Products but significant challenges in Communications Systems. Operational inefficiencies, delays in government contracts, and a net loss due to impairment charges weigh negatively. The Q&A section reveals management's lack of clarity on timelines for key projects, adding uncertainty. Despite some positive aspects like backlog growth and new medical orders, the overall sentiment is negative, especially given the financial losses and strategic risks.